phrykt

Evommune, Inc. (EVMN): who owns it and who trades it

As of Nov 16, 2026, EVMN insiders reported 9 open-market sales worth $2.3M and 3 purchases worth $164K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Luis C. Pena (CEO), with $551K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Evommune

From the latest filings

Overall: more buying than selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns EVMN

105 funds and institutions reported EVMN shares worth $465M at the end of Q2 2026, about 97% of the company. The largest holder is EQT Fund Management S.a r.l. with 14.7%.

Funds and institutions (13F) 97%Everyone else 3%

10 largest owners, by share of the company

EQT Fund Management S.a r.l.14.7%
Ra Capital Management, L.P.9.7%
T. Rowe Price Associates5.4%
Pivotal bioVenture Partners Investment Advisor LLC5.3%
JPMorgan Chase & Co4.3%
Rtw Investments, LP4.2%
Nan Fung Group Holdings Ltd4.0%
Point72 Asset Management, L.P.4.0%
Andera Partners3.9%
Eventide Asset Management, LLC3.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
EQT Fund Management S.a r.l.5.29M14.68%$70.3M+7%
Ra Capital Management, L.P.3.49M9.70%$46.4MNo change
T. Rowe Price Associates1.94M5.39%$25.8M+73%
Pivotal bioVenture Partners Investment Advisor LLC1.93M5.35%$25.6MNo change
JPMorgan Chase & Co1.55M4.31%$23.4MNew
Rtw Investments, LP1.50M4.17%$20MNo change
Nan Fung Group Holdings Ltd1.44M4.00%$19.2MNo change
Point72 Asset Management, L.P.1.44M3.98%$19.1M+3823%
Andera Partners1.39M3.86%$18.5M-27%
Eventide Asset Management, LLC1.21M3.36%$16.1MNo change
Vestal Point Capital, LP1.00M2.78%$13.3MNew
Jupiter Topco LLC896,7002.49%$11.9MNew
BlackRock, Inc.886,5382.46%$11.8M+32%
Vanguard Capital Management LLC881,8952.45%$11.7M+94%
Baker Bros. Advisors LP847,3902.35%$11.3MNo change
Defilade Capital Management, L.P.793,1452.20%$10.5M+17%
American Century Companies Inc755,0182.10%$10M+53%
Alyeska Investment Group, L.P.704,4251.96%$9.4M-3%
Balyasny Asset Management L.P.457,0151.27%$6.1MNew
Velan Capital Investment Management LP451,2551.25%$6M+1%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, EVMN insiders reported $164K of open-market purchases and $2.3M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$164K
3 trades, 3 people
Sales, 12 months
$2.3M
9 trades, 6 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Jul 8, 2026
Filed Jul 10, 2026

Purchases and sales by month

$1.5M$1.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jul 8, 2026Kyle CarverCFOPurchase1,000$13.26$13.3KForm 4
Jul 7, 2026Arthur S KirschDirectorPurchase10,000$13.30$133KForm 4
Jun 22, 2026Janice Suzann DrewChief of Dev. OperationsSale20,000$22.63$453KForm 4
Jun 22, 2026Jeegar Pravinkumar PatelChief Scientific OfficerSale1,488$22.50$33.5KForm 4
Jun 22, 2026Luis C. PenaCEOSale7,438$22.71$169KForm 4
Jun 2, 2026David E CohenDirectorSale5,456$20.21$110KForm 4
Jun 2, 2026David E CohenDirectorSale600$21.38$12.8KForm 4
Jun 1, 2026Jeegar Pravinkumar PatelChief Scientific OfficerSale16,687$22.74$379KForm 4
Jun 1, 2026Luis C. PenaCEOSale16,787$22.74$382KForm 4
May 28, 2026Gregory S. MossChief Business & Legal OSale14,223$22.83$325KForm 4
May 28, 2026Kyle CarverCFOSale18,175$22.84$415KForm 4
Dec 19, 2025Robert Lorne HopfnerDirectorPurchase1,000$17.35$17.4KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Luis C. PenaPresident & CEO, Director–$551KJun 22, 2026
Janice Suzann DrewChief of Dev. Operations–$453KJun 22, 2026
Kyle CarverChief Financial Officer$13.3K$415KJul 8, 2026
Jeegar Pravinkumar PatelChief Scientific Officer–$413KJun 22, 2026
Gregory S. MossChief Business & Legal Officer–$325KMay 28, 2026
Arthur S KirschDirector$133K–Jul 7, 2026
David E CohenDirector–$123KJun 2, 2026
Robert Lorne HopfnerDirector, 10% owner$17.4K–Dec 19, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

EVMN short interest

Moderate short interest. 9.3% of EVMN shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went up 9%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.39M EVMN shares were sold short, 9.3% of the shares outstanding, down 4.1% from the report before. At the average daily volume of 1.15M shares, buying them all back would take about 3.0 trading days (days to cover).

Shares short, % of all shares

9.33%May 15Oct 3014.1%

Days to cover

3.0May 15Oct 3013.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.39M9.33%-4%1.15M3.0
Oct 15, 20263.53M9.74%+22%1.03M3.4
Sep 30, 20262.89M7.97%+1%749,5253.9
Sep 15, 20262.88M7.93%-34%866,6373.3
Aug 31, 20264.36M12.03%-7%375,19611.6
Aug 14, 20264.70M12.94%+5%571,9938.2
Jul 31, 20264.48M12.44%+12%517,0458.7
Jul 15, 20264.02M11.15%-16%1.10M3.7
Jun 30, 20264.78M13.27%+12%1.81M2.6
Jun 15, 20264.27M11.85%+7%451,7289.4
May 29, 20263.98M11.04%+28%431,9589.2
May 15, 20263.10M8.60%-5%433,3807.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Evommune company events

Evommune filed 16 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.

  1. Nov 5, 2026AnnouncementShared information with investors. Filing
  2. Nov 4, 2026AgreementEvommune, Inc. entered into an Exclusive License Agreement with Hinova Pharmaceuticals Inc., a company incorporated in the People’s Republic of China. Filing
  3. Oct 1, 2026AnnouncementShared information with investors. Filing
  4. Sep 23, 2026AnnouncementShared information with investors. Filing
  5. Sep 15, 2026AnnouncementShared information with investors. Filing
  6. Sep 9, 2026AnnouncementThe Company issued a press release announcing top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial evaluating the efficacy and safety of oral MRGPRX2 antagonist, EVO756, in adults with moderate-to-severe Atopic Dermatitis. Filing
  7. Aug 6, 2026ResultsReleased financial results. Filing
  8. Jul 30, 2026AnnouncementShared information with investors. Filing
  9. Jun 29, 2026AnnouncementThe Company issued a press release announcing top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial evaluating the efficacy and safety of oral MRGPRX2 antagonist, EVO756, in adults with moderate-to-severe chronic spontaneous urticaria. Filing
  10. Jun 2, 2026VoteReported shareholder vote results. Filing
  11. May 7, 2026ResultsReleased financial results. Filing
  12. Apr 13, 2026AnnouncementShared information with investors. Filing
  13. Mar 5, 2026ResultsReleased financial results. Filing
  14. Feb 13, 2026AgreementEvommune, Inc. entered into a Securities Purchase Agreement with certain investors pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 4,494,279 shares of the Company’s common stock, par value $0.0001 per share. Filing
  15. Feb 10, 2026AnnouncementShared information with investors. Filing
  16. Dec 11, 2025ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Evommune financials

Famous investors that hold EVMN

3 of the 50 well-known investors we track reported holding EVMN in their latest 13F filing. The largest position is Steve Cohen's, worth $20.1M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 20262.43M$20.1M0.0%+70%
Israel Englander · Millennium ManagementQ3 2026847,296$7M0.0%New
Ken Griffin · Citadel AdvisorsQ3 2026379,729$3.1M0.0%+3441%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named EVMN in the last 120 days.

FiledHolderFormStake
Nov 16, 2026T. Rowe Price Associates, Inc.13G/A2.3%
Nov 16, 2026Point72 Asset Management, L.P.13G/A6.7%
Nov 16, 2026T. Rowe Price Associates, Inc.13G/A2.3%
Nov 16, 2026Point72 Asset Management, L.P.13G/A6.7%
Nov 10, 2026RA Capital Management, L.P.13D/A8.5%
Nov 10, 2026RA Capital Management, L.P.13D/A8.5%

Questions about Evommune, Inc. (EVMN) stock

Who owns the most EVMN stock?

The largest reported owner of Evommune, Inc. (EVMN) is EQT Fund Management S.a r.l., with 14.7% of the company. In total, 105 funds and institutions reported holding EVMN at the end of Q2 2026, together about 97% of the shares. See the largest owners.

Are EVMN insiders buying or selling?

In the last 12 months, EVMN insiders reported 3 open-market purchases worth $164K and 9 sales worth $2.3M. The latest trade was on Jul 8, 2026. See every trade.

What is the short interest in EVMN?

As of Oct 30, 2026, 3.39M EVMN shares were sold short, 9.3% of the shares outstanding, down 4.1% from the report before. At the average daily volume of 1.15M shares, buying them all back would take about 3.0 trading days (days to cover). See the history.

Which famous investors hold EVMN?

3 of the 50 well-known investors we track reported EVMN in their latest 13F filing, including Steve Cohen, Israel Englander, Ken Griffin. The largest position is worth $20.1M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.